Hydra Biosciences

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2001.

The company focuses on developing innovative drugs to address unmet medical needs in areas such as pain, inflammation, anxiety, pulmonary diseases, depressive disorders, renal fibrosis, and heart tissue regeneration. Hydra Biosciences has pioneered drug discovery through proprietary platforms that target Transient Receptor Potential (TRP) ion channels and molecular regeneration techniques. The company has developed a pipeline of therapeutics, including HC-070, which is in Phase 1 for depressive disorder, and BI-749327, currently in preclinical development for renal fibrosis. As of now, Hydra Biosciences is in the Asset Sale stage, having sold its programs and assets. The company has raised a total of $95.18 million in funding, with notable investments from firms like NEA and Eli Lilly, which acquired its pre-clinical pain program.